tirzepatide microneedle patch reviews 𝑳𝒆𝒓𝒄𝒆𝒂® 𝐍𝐈𝐃𝐃𝐊-𝐓𝐢𝐫𝐳𝐞𝐩𝐚𝐭𝐢𝐝𝐞 𝐒𝐥𝐢𝐦𝐦𝐢𝐧𝐠 & 𝐡𝐞𝐚𝐥𝐭𝐡 𝐍𝐀𝐍𝐎 𝐌𝐈𝐂𝐑𝐎𝐍𝐄𝐄𝐃𝐋𝐄 𝐏𝐀𝐓𝐂𝐇 NIDDK Tirzepatide Microneedle Patch Review

Pearsons correlation was calculated using R software (version 4.2.2)

Drug class Mounjaro: Dual GIP + GLP-1 receptor agonist Wegovy: GLP-1 receptor agonist Active ingredient Mounjaro: Tirzepatide Wegovy: Semaglutide Dosing Both: Once-weekly subcutaneous injection Similar escalation schedules, but different titration protocols Mechanism Mounjaro: Targets two incretin pathways (GIP + GLP-1), enhancing metabolic and appetite effects Wegovy: Targets GLP-1 pathway only Weight loss efficacy Mounjaro: Up to ~15% weight reduction in clinical trials Wegovy: ~1015% average body weight reduction Clinical use Mounjaro: Often considered more potent option Wegovy: Established first-line GLP-1 obesity therapy Saxenda vs Wegovy Saxenda is a prescription injectable treatment used in adults who are obese or overweight

doi: 10.1186/1750-1172-7-S1-S4

While semaglutide is administered once weekly, tirzepatide offers a slightly broader titration window